Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers
1. Azd7986
2. Ins-1007
3. Ins1007
4. N-(1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
1. Azd7986
2. 1802148-05-5
3. Ins1007
4. (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
5. Brensocatib [usan]
6. Azd 7986
7. Azd-7986
8. Ins-1007
9. 25cg88l0bb
10. Chembl3900409
11. (2s)-n-[(1s)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
12. (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
13. 1,4-oxazepine-2-carboxamide, N-((1s)-1-cyano-2-(4-(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)phenyl)ethyl)hexahydro-, (2s)-
14. Ins 1007
15. Brensocatib [inn]
16. Unii-25cg88l0bb
17. Brensocatib [who-dd]
18. Gtpl9412
19. Schembl16932317
20. Ex-a1866
21. Bdbm50195235
22. Pz1130
23. Who 11097
24. Ac-36222
25. As-84225
26. Bb177302
27. Hy-101056
28. Cs-0020766
29. J3.556.230c
30. A17095
31. D84088
32. A937370
33. (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
34. (s)-3-[4-(2-oxo-3-methyl-2,3-dihydrobenzoxazole-5-yl)phenyl]-2-[(hexahydro-1,4-oxazepine-2alpha-yl)carbonylamino]propanenitrile
Molecular Weight | 420.5 g/mol |
---|---|
Molecular Formula | C23H24N4O4 |
XLogP3 | 2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 420.17975526 g/mol |
Monoisotopic Mass | 420.17975526 g/mol |
Topological Polar Surface Area | 104 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 699 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of non-cystic fibrosis bronchiectasis
Details:
Brinsupri (brensocatib) is the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Brinsupri
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2025
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Insmed's Brinsupri nabs landmark FDA nod in chronic lung disease
Details : Brinsupri (brensocatib) is the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
Product Name : Brinsupri
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2025
Details:
Insmed intends to use the net proceeds to fund continued research and development of INS1007 (brensocatib), for non-cystic fibrosis bronchiectasis.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Goldman Sachs & Co
Deal Size: $750.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 11, 2025
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co
Deal Size : $750.0 million
Deal Type : Public Offering
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
Details : Insmed intends to use the net proceeds to fund continued research and development of INS1007 (brensocatib), for non-cystic fibrosis bronchiectasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 11, 2025
Details:
INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2025
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Won’t Hold Advisory Meeting to Discuss NDA for Brensocatib
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2025
Details:
Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hidradenitis Suppurativa.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 13, 2024
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hidradenitis Suppurativa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 13, 2024
Details:
INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 08, 2024
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ASPEN Study Subgroup Shows Consistency in Brensocatib’s Efficacy in Bronchiectasis
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2024
Details:
Insmed intends to use the proceeds to fund continued research and development of INS1007 (brensocatib) as well as pre-commercial and, if approved, commercialization activities related to brensocatib.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Goldman Sachs & Co
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 30, 2024
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co
Deal Size : $650.0 million
Deal Type : Public Offering
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Details : Insmed intends to use the proceeds to fund continued research and development of INS1007 (brensocatib) as well as pre-commercial and, if approved, commercialization activities related to brensocatib.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 30, 2024
Details:
The net proceeds will fund continued research and development of INS1007 (brensocatib), a small molecule, oral, reversible inhibitor of DPP1, for non-cystic fibrosis bronchiectasis.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Goldman Sachs & Co
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2024
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co
Deal Size : $500.0 million
Deal Type : Public Offering
Insmed Announces Proposed $500 Million Public Offering of Common Stock
Details : The net proceeds will fund continued research and development of INS1007 (brensocatib), a small molecule, oral, reversible inhibitor of DPP1, for non-cystic fibrosis bronchiectasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 28, 2024
Details:
INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2024
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Insmed Announces Positive Results from ASPEN Study of Brensocatib in Bronchiectasis
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2024
Details:
Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2024
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2024
Details:
Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Brensocatib,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 21, 2023
Lead Product(s) : Brensocatib,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2023
RLD : Yes
TE Code :
Brand Name : BRINSUPRI
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2025-08-12
Application Number : 217673
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : BRINSUPRI
Dosage Form : TABLET;ORAL
Dosage Strength : 25MG
Approval Date : 2025-08-12
Application Number : 217673
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Market Place
Reply
22 Sep 2025
Patents & EXCLUSIVITIES
Patent Expiration Date : 2035-01-21
US Patent Number : 9815805
Drug Substance Claim :
Drug Product Claim :
Application Number : 217673
Patent Use Code : U-4257
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-21
Patent Expiration Date : 2035-01-21
US Patent Number : 11655222
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 217673
Patent Use Code : U-4257
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-21
Patent Expiration Date : 2035-01-21
US Patent Number : 11773069
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217673
Patent Use Code : U-4257
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-21
Patent Expiration Date : 2035-01-21
US Patent Number : 9815805
Drug Substance Claim :
Drug Product Claim :
Application Number : 217673
Patent Use Code : U-4257
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-21
Patent Expiration Date : 2035-01-21
US Patent Number : 11655222
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 217673
Patent Use Code : U-4257
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-21
Patent Expiration Date : 2035-01-21
US Patent Number : 11673871
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217673
Patent Use Code : U-4257
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-21
Patent Expiration Date : 2039-03-01
US Patent Number : 12201638
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217673
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-03-01
Patent Expiration Date : 2035-01-21
US Patent Number : 11655221
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217673
Patent Use Code : U-4257
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-21
Patent Expiration Date : 2035-01-21
US Patent Number : 11673871
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217673
Patent Use Code : U-4257
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-21
Patent Expiration Date : 2039-03-01
US Patent Number : 12201638
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217673
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-03-01
Exclusivity Code : NCE
Exclusivity Expiration Date : 2030-08-12
Application Number : 217673
Product Number : 1
Exclusivity Details :
Exclusivity Code : NCE
Exclusivity Expiration Date : 2030-08-12
Application Number : 217673
Product Number : 2
Exclusivity Details :
ABOUT THIS PAGE
57
PharmaCompass offers a list of Brensocatib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Brensocatib manufacturer or Brensocatib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Brensocatib manufacturer or Brensocatib supplier.
PharmaCompass also assists you with knowing the Brensocatib API Price utilized in the formulation of products. Brensocatib API Price is not always fixed or binding as the Brensocatib Price is obtained through a variety of data sources. The Brensocatib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Brensocatib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Brensocatib, including repackagers and relabelers. The FDA regulates Brensocatib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Brensocatib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Brensocatib supplier is an individual or a company that provides Brensocatib active pharmaceutical ingredient (API) or Brensocatib finished formulations upon request. The Brensocatib suppliers may include Brensocatib API manufacturers, exporters, distributors and traders.
Brensocatib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Brensocatib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Brensocatib GMP manufacturer or Brensocatib GMP API supplier for your needs.
A Brensocatib CoA (Certificate of Analysis) is a formal document that attests to Brensocatib's compliance with Brensocatib specifications and serves as a tool for batch-level quality control.
Brensocatib CoA mostly includes findings from lab analyses of a specific batch. For each Brensocatib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Brensocatib may be tested according to a variety of international standards, such as European Pharmacopoeia (Brensocatib EP), Brensocatib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Brensocatib USP).